Bill Taranto

So we just can't be in a corporate practice of medicine.

But there's a lot of things we do in this space around enabling access to medicines and delivery to the right patient to ensure optimal outcomes.

And these are things like social determinants of health, patient-centric care,

It could be commercial data analytics, clinical decision support tools, remote monitoring, you know, things where we can support the patient, but not necessarily in the practice of medicine.

And then the last bucket we focus on is evidence generation.

This is real world evidence and real world data.

So how do we give either Merck or the community access to data globally and then provide informatics and analytics on top of that?

And if you think about that four buckets, that's really the pharmaceutical value chain of where we're trying to promote.

And what we do is we work with Merck on identifying their use case and what are the big problems they're trying to solve.

That's what we mean by a use case, as well as the industry, because if it's good for Merck, it's good for the industry.

If it's good to the industry, it's good for Merck.

So we're trying to solve, I would say, more enterprise solutions than really specific point solutions.

as we think about it.

But that's sort of a 60,000 foot view of the fund and what we do today.

As I said, we're mostly growth equity, series C or later.

We'll do A and B rounds occasionally, but we do not do startup or seed capital.

That's not part of our charter as we think about where we invest and how we think about the kind of ecosystems that we build going forward.

What was a bit odd, I will say, when I got the call from Merck, it was a call out of the blue.

And basically, they said that they were very interested in starting a technology or digital.

It wasn't called digital.